Peter Jones
Laboratory
Epigenetic Therapies
Our laboratory focuses on the mechanisms by which epigenetic processes become misregulated in cancer and contribute to the disease phenotype. We focus on the role of DNA methylation in controlling the expression of genes during normal development and in cancer. Our work has shifted to a holistic approach in which we are interested in the interactions between processes such as DNA methylation, histone modification and nucleosomal positioning to structure the epigenome and we want to determine how mutations in the genes which modify the epigenome contribute to the cancer phenotype. We have had a longstanding interest in the mechanism of action of DNA methylation inhibitors both in the lab and in the clinic. In the clinic, we are working with several major institutions to bring epigenetic therapies to the forefront of cancer medicine.
About Epigenetics
Epigenetics may be defined as mitotically heritable changes in gene expression which are not caused by changes in the DNA sequence itself. Epigenetic processes establish the differentiated state of cells and govern how genes are used in the different cells in our bodies to allow organs and different cell types to function correctly and inherit their properties through cell division. These processes can go wrong during the formation of diseases including cancer and thus change the behavior of cells so that they don’t perform as they should. Importantly, many of these changes are potentially reversible and can be changed by treatment with appropriate drugs. Since epigenetic processes are at the root of biology they have implications in all of human development and disease.
Our Impact
We’re raising thousands to save millions.
We’re turning hope into action for the millions of people around the world affected by diseases like cancer and Parkinson’s. Find out how you can help us make a difference.
- 141 peer-reviewed papers published in 2025, 74 of which were in high-impact journals
- 15 VAI-SU2C Epigenetics Dream Team clinical trials launched to date
- 10 clinical trials and related projects supported by VAI through the International Linked Clinical Trials Program
Peter A. Jones, Ph.D., D.Sc. (hon)
Distinguished Professor, Department of Epigenetics
Areas of Expertise
Epigenetics, DNA methylation, epigenetic therapies
Biography
Dr. Peter A. Jones was born in Cape Town, raised and attended college in Rhodesia (now Zimbabwe), and received his Ph.D. from the University of London. He joined the University of Southern California in 1977 and served as director of the USC Norris Comprehensive Cancer Center between 1993 and 2011. In 2014, he was appointed chief scientific officer of Van Andel Institute in Grand Rapids, Michigan, a position he held until he returned to the lab full time in 2026. Jones also served as president of VAI and its Graduate School from 2024 to 2026. Under his leadership, the Institute grew into a world leader in cancer epigenetics and was ranked no. 5 among North American nonprofit research institutes in biological sciences by the Nature Index in 2025.
His laboratory discovered the effects of 5-azacytidine on cytosine methylation and he first established the link between DNA methylation, gene expression and differentiation. He pioneered the field of epigenetics, particularly its role in cancer, and helped develop novel therapies for cancer. Dr. Jones is a past president of the American Association for Cancer Research, a Fellow of the AACR Academy, a Fellow of the American Association for the Advancement of Science, a member of the National Academy of Sciences, a member of National Academy of Medicine and a fellow of the American Academy of Arts and Sciences. He has published more than 300 scientific papers and received several honors, including the Outstanding Investigator Award from the National Cancer Institute. He and his colleague Dr. Stephen Baylin shared the Kirk A. Landon Award for Basic Cancer Research from the AACR in 2009 and the Medal of Honor from the American Cancer Society in 2011. He shared the 2022-2023 Harvey Prize in Science and Technology with Drs. Stephen Baylin and Andrew Feinberg for their groundbreaking work in cancer epigenetics.
Selected Publications
For a full list of publications, please visit Google Scholar ➔
Braelyn Binkowski
Ph.D. Student, VAI Graduate School
Research focus to be determined.
Jennifer Brooks
Senior Administrative Assistant I, Department of Epigenetics
Xiaoying Chen, Ph.D.
Postdoctoral Fellow, Jones Laboratory
Minmin Liu, Ph.D.
Senior Research Scientist, Department of Epigenetics
Rachel Shereda, B.S.
Research Technician, Department of Epigenetics
Stacey Thomas, Ph.D.
Senior Lab Manager, Department of Epigenetics
Guillermo Urrutia, M.D.
Research Scientist, Department of Epigenetics